Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1

Journal of Biological Chemistry

Volumn 289, Issue 13, 2014, Pages 9304-9319

  Jung, Marie ^a,b   Philpott, Martin ^c   Müller, Susanne ^c   Schulze, Jessica ^a   Badock, Volker ^a   Eberspächer, Uwe ^a   Moosmayer, Dieter ^a   Bader, Benjamin ^a   Schmees, Norbert ^a   Fernández Montalván, Amaury ^a   Haendler, Bernard ^a  

^a BAYER PHARMA AG   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CELL PROLIFERATION;

BIOPHYSICAL METHODS; CELLULAR ENVIRONMENT; PHARMACOLOGICAL PROPERTIES; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROTEIN FAMILY; RNA POLYMERASE II; SMALL MOLECULE INHIBITOR; TERMINAL DOMAIN;

PROTEINS;

ASPARAGINE; ASPARAGINE 140; ASPARTIC ACID; ASPARTIC ACID 145; BD1 PROTEIN; BD2 PROTEIN; BROMODOMAIN PROTEIN 4; HISTONE H3; HISTONE H4; ISOLEUCINE; ISOLEUCINE 146; LEUCINE; LEUCINE 94; LYSINE; METHIONINE; METHIONINE 149; PROLINE; PROLINE 82; PROTEIN; RNA POLYMERASE II; TRANSCRIPTION FACTOR T BET; TRYPTOPHAN; TRYPTOPHAN 81; TYROSINE; TYROSINE 97; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; BRD4 PROTEIN, HUMAN; CHROMATIN; HISTONE; LIGAND; NUCLEAR PROTEIN; PEPTIDE FRAGMENT; PROTEIN BINDING; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CRYSTAL STRUCTURE; HISTONE ACETYLATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION ELONGATION; ACETYLATION; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; CHROMATIN; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MOLECULAR GENETICS; MUTATION; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE; SITE DIRECTED MUTAGENESIS;

ACETYLATION; AMINO ACID SEQUENCE; ANIMALS; AZEPINES; CHROMATIN; HEK293 CELLS; HISTONES; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTATION; NUCLEAR PROTEINS; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; TRANSCRIPTION FACTORS; TRIAZOLES;

EID: 84897448118     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.523019     Document Type: Article

References (67)

1. Berger, S. L. (2007) The complex language of chromatin regulation during transcription. Nature 447, 407-412
2. Bannister, A. J., and Kouzarides, T. (2011) Regulation of chromatin by histone modifications. Cell Res. 21, 381-395
3. Zeng, L., and Zhou, M. M. (2002) Bromodomain. An acetyl-lysine binding domain. FEBS Lett. 513, 124-128
4. Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J. P., Barsyte-Lovejoy, D., Felletar, I., Volkmer, R., Müller, S., Pawson, T., Gingras, A. C., Arrowsmith, C. H., and Knapp, S. (2012) Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149, 214-231
5. Florence, B., and Faller, D. V. (2001) You bet-cha. A novel family of transcriptional regulators. Front Biosci. 6, D1008-D1018
6. Vidler, L. R., Brown, N., Knapp, S., and Hoelder, S. (2012) Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J. Med. Chem. 55, 7346-7359
7. Wang, R., Li, Q., Helfer, C. M., Jiao, J., and You, J. (2012) The bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structure. J. Biol. Chem. 287, 10738-10752
8. Jang, M. K., Mochizuki, K., Zhou, M., Jeong, H. S., Brady, J. N., and Ozato, K. (2005) The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 19, 523-534 (Pubitemid 41140009)
9. Schröder, S., Cho, S., Zeng, L., Zhang, Q., Kaehlcke, K., Mak, L., Lau, J., Bisgrove, D., Schnölzer, M., Verdin, E., Zhou, M. M., and Ott, M. (2012) Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes. J. Biol. Chem. 287, 1090-1099
10. Yang, Z., He, N., and Zhou, Q. (2008) Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol. Cell. Biol. 28, 967-976 (Pubitemid 351160053)
11. Chiang, C. M. (2009) Brd4 engagement from chromatin targeting to transcriptional regulation. Selective contact with acetylated histone H3 and H4. F1000 Biol. Rep. 1, 98
12. Zhang, W., Prakash, C., Sum, C., Gong, Y., Li, Y., Kwok, J. J., Thiessen, N., Pettersson, S., Jones, S. J., Knapp, S., Yang, H., and Chin, K. C. (2012) Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J. Biol. Chem. 287, 43137-43155
13. Zhang, G., Liu, R., Zhong, Y., Plotnikov, A. N., Zhang, W., Zeng, L., Rusinova, E., Gerona-Nevarro, G., Moshkina, N., Joshua, J., Chuang, P. Y., Ohlmeyer, M., He, J. C., and Zhou, M. M. (2012) Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J. Biol. Chem. 287, 28840-28851
14. Zou, Z., Huang, B., Wu, X., Zhang, H., Qi, J., Bradner, J., Nair, S., and Chen, L. F. (2013) Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA. Oncogene 10.1038/onc.2013.179
15. Rahman, S., Sowa, M. E., Ottinger, M., Smith, J. A., Shi, Y., Harper, J. W., and Howley, P. M. (2011) The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol. Cell. Biol. 31, 2641-2652
16. Oliver, S. S., and Denu, J. M. (2011) Disrupting the reader of histone language. Angew Chem. Int. Ed. Engl. 50, 5801-5803
17. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., Philpott, M., Munro, S., McKeown, M. R., Wang, Y., Christie, A. L., West, N., Cameron, M. J., Schwartz, B., Heightman, T. D., La Thangue, N., French, C. A., Wiest, O., Kung, A. L., Knapp, S., and Bradner, J. E. (2010) Selective inhibition of BET bromodomains. Nature 468, 1067-1073
18. Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C. W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., White, J., Kirilovsky, J., Rice, C. M., Lora, J. M., Prinjha, R. K., Lee, K., and Tarakhovsky, A. (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119-1123
19. Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W. I., Robson, S. C., Chung, C. W., Hopf, C., Savitski, M. M., Huthmacher, C., Gudgin, E., Lugo, D., Beinke, S., Chapman, T. D., Roberts, E. J., Soden, P. E., Auger, K. R., Mirguet, O., Doehner, K., Delwel, R., Burnett, A. K., Jeffrey, P., Drewes, G., Lee, K., Huntly, B. J., and Kouzarides, T. (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529-533
20. Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., Chesi, M., Schinzel, A. C., McKeown, M. R., Heffernan, T. P., Vakoc, C. R., Bergsagel, P. L., Ghobrial, I. M., Richardson, P. G., Young, R. A., Hahn, W. C., Anderson, K. C., Kung, A. L., Bradner, J. E., and Mitsiades, C. S. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904-917
21. Mertz, J. A., Conery, A. R., Bryant, B. M., Sandy, P., Balasubramanian, S., Mele, D. A., Bergeron, L., and Sims, R. J., 3rd. (2011) Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. U.S.A. 108, 16669-16674
22. Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., and Young, R. A. (2013) Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320-334
23. Wu, S. Y., Lee, A. Y., Lai, H. T., Zhang, H., and Chiang, C. M. (2013) Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol. Cell 49, 843-857
24. French, C. A., Miyoshi, I., Aster, J. C., Kubonishi, I., Kroll, T. G., Dal Cin, P., Vargas, S. O., Perez-Atayde, A. R., and Fletcher, J. A. (2001) BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19). Am. J. Pathol. 159, 1987-1992 (Pubitemid 33104253)
25. French, C. A., Miyoshi, I., Kubonishi, I., Grier, H. E., Perez-Atayde, A. R., and Fletcher, J. A. (2003) BRD4-NUT fusion oncogene. A novel mechanism in aggressive carcinoma. Cancer Res. 63, 304-307 (Pubitemid 36152484)
26. French, C. A. (2013) The importance of diagnosing NUT midline carcinoma. Head Neck Pathol. 7, 11-16
27. Herrmann, H., Blatt, K., Shi, J., Gleixner, K. V., Cerny-Reiterer, S., Müllauer, L., Vakoc, C. R., Sperr, W. R., Horny, H. P., Bradner, J. E., Zuber, J., and Valent, P. (2012) Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem and progenitor cells in acute myeloid leukemia AML. Oncotarget. 3, 1588-1599
28. Da Costa, D., Agathanggelou, A., Perry, T., Weston, V., Petermann, E., Zlatanou, A., Oldreive, C., Wei, W., Stewart, G., Longman, J., Smith, E., Kearns, P., Knapp, S., and Stankovic, T. (2013) BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J. 3, e126
29. Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., Taylor, M. J., Johns, C., Chicas, A., Mulloy, J. C., Kogan, S. C., Brown, P., Valent, P., Bradner, J. E., Lowe, S. W., and Vakoc, C. R. (2011) RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528
30. Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chanthery, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., Garnett, M. J., McDermott, U., Benes, C. H., Kung, A. L., Weiss, W. A., Bradner, J. E., and Stegmaier, K. (2013) Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 3, 308-323
31. Wyce, A., Ganji, G., Smitheman, K. N., Chung, C. W., Korenchuk, S., Bai, Y., Barbash, O., Le, B., Craggs, P. D., McCabe, M. T., Kennedy-Wilson, K. M., Sanchez, L. V., Gosmini, R. L., Parr, N., McHugh, C. F., Dhanak, D., Prinjha, R. K., Auger, K. R., and Tummino, P. J. (2013) BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS ONE 8, e72967
32. Lockwood, W. W., Zejnullahu, K., Bradner, J. E., and Varmus, H. (2012) Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc. Natl. Acad. Sci. U.S.A. 109, 19408-19413
33. Shimamura, T., Chen, Z., Soucheray, M., Carretero, J., Kikuchi, E., Tchaicha, J. H., Gao, Y., Cheng, K. A., Cohoon, T. J., Qi, J., Akbay, E., Kimmelman, A. C., Kung, A. L., Bradner, J. E., and Wong, K. K. (2013) Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin. Cancer Res. 19, 6183-6192
34. Segura, M. F., Fontanals-Cirera, B., Gaziel-Sovran, A., Guijarro, M. V., Hanniford, D., Zhang, G., González-Gomez, P., Morante, M., Jubierre, L., Zhang, W., Darvishian, F., Ohlmeyer, M., Osman, I., Zhou, M. M., and Hernando, E. (2013) BRD4 sustains proliferation and represents a new target for epigenetic therapy in melanoma. Cancer Res. 73, 6264-6276
35. Weidner-Glunde, M., Ottinger, M., and Schulz, T. F. (2010) WHAT do viruses BET on? Front. Biosci. 15, 537-549
36. Dhalluin, C., Carlson, J. E., Zeng, L., He, C., Aggarwal, A. K., and Zhou, M. M. (1999) Structure and ligand of a histone acetyltransferase bromodomain. Nature 399, 491-496 (Pubitemid 29258857)
37. Owen, D. J., Ornaghi, P., Yang, J. C., Lowe, N., Evans, P. R., Ballario, P., Neuhaus, D., Filetici, P., and Travers, A. A. (2000) The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. EMBO J. 19, 6141-6149
38. Umehara, T., Nakamura, Y., Jang, M. K., Nakano, K., Tanaka, A., Ozato, K., Padmanabhan, B., and Yokoyama, S. (2010) Structural basis for acetylated histone H4 recognition by the human BRD2 bromodomain. J. Biol. Chem. 285, 7610-7618
39. Vollmuth, F., Blankenfeldt, W., and Geyer, M. (2009) Structures of the dual bromodomains of the P-TEFb-activating protein Brd4 at atomic resolution. J. Biol. Chem. 284, 36547-36556
40. Dey, A., Chitsaz, F., Abbasi, A., Misteli, T., and Ozato, K. (2003) The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc. Natl. Acad. Sci. U.S.A. 100, 8758-8763 (Pubitemid 36899172)
41. Ito, T., Umehara, T., Sasaki, K., Nakamura, Y., Nishino, N., Terada, T., Shirouzu, M., Padmanabhan, B., Yokoyama, S., Ito, A., and Yoshida, M. (2011) Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors. Chem. Biol. 18, 495-507
42. Kanno, T., Kanno, Y., Siegel, R. M., Jang, M. K., Lenardo, M. J., and Ozato, K. (2004) Selective recognition of acetylated histones by bromodomain proteins visualized in living cells. Mol. Cell 13, 33-43 (Pubitemid 38117113)
43. Morinière, J., Rousseaux, S., Steuerwald, U., Soler-López, M., Curtet, S., Vitte, A. L., Govin, J., Gaucher, J., Sadoul, K., Hart, D. J., Krijgsveld, J., Khochbin, S., Müller, C. W., and Petosa, C. (2009) Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature 461, 664-668
44. Pivot-Pajot, C., Caron, C., Govin, J., Vion, A., Rousseaux, S., and Khochbin, S. (2003) Acetylation-dependent chromatin reorganization by BRDT, a testis-specific bromodomain-containing protein. Mol. Cell. Biol. 23, 5354-5365 (Pubitemid 36950890)
45. Gamsjaeger, R., Webb, S. R., Lamonica, J. M., Billin, A., Blobel, G. A., and Mackay, J. P. (2011) Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3. Mol. Cell. Biol. 31, 2632-2640
46. Sierra, J. R., Cepero, V., and Giordano, S. (2010) Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol. Cancer 9, 75
47. Zhang, J., Yang, P. L., and Gray, N. S. (2009) Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28-39
48. Yun, C. H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K. K., Meyerson, M., and Eck, M. J. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. U.S.A. 105, 2070-2075 (Pubitemid 351439466)
49. Durocher, Y., Perret, S., and Kamen, A. (2002) High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 30, E9
50. Barik, S. (1993) Site-directed mutagenesis by double polymerase chain reaction. Megaprimer method. Methods Mol. Biol. 15, 277-286
51. Brandts, J. F., and Lin, L. N. (1990) Study of strong to ultratight protein interactions using differential scanning calorimetry. Biochemistry 29, 6927-6940 (Pubitemid 20225495)
52. Myers, J. K., Pace, C. N., and Scholtz, J. M. (1995) Denaturantmvalues and heat capacity changes. Relation to changes in accessible surface areas of protein unfolding. Protein Sci. 4, 2138-2148
53. Layton, C. J., and Hellinga, H. W. (2010) Thermodynamic analysis of ligand-induced changes in protein thermal unfolding applied to high-throughput determination of ligand affinities with extrinsic fluorescent dyes. Biochemistry 49, 10831-10841
54. 50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108
55. Picaud, S., Da Costa, D., Thanasopoulou, A., Filippakopoulos, P., Fish, P. V., Philpott, M., Fedorov, O., Brennan, P., Bunnage, M. E., Owen, D. R., Bradner, J. E., Taniere, P., O'Sullivan, B., Müller, S., Schwaller, J., Stankovic, T., and Knapp, S. (2013) PFI-1. A highly selective protein interaction inhibitor targeting BET bromodomains. Cancer Res. 73, 3336-3346
56. Phair, R. D., Gorski, S. A., and Misteli, T. (2004) Measurement of dynamic protein binding to chromatin in vivo, using photobleaching microscopy. Methods Enzymol. 375, 393-414 (Pubitemid 38124881)
57. Huang, B., Yang, X. D., Zhou, M. M., Ozato, K., and Chen, L. F. (2009) Brd4 coactivates transcriptional activation of NF-κB via specific binding to acetylated RelA. Mol. Cell. Biol. 29, 1375-1387
58. Chung, C. W., and Witherington, J. (2011) Progress in the discovery of small-molecule inhibitors of bromodomain-histone interactions. J. Biomol. Screen 16, 1170-1185
59. Matulis, D., Kranz, J. K., Salemme, F. R., and Todd, M. J. (2005) Thermodynamic stability of carbonic anhydrase. Measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry 44, 5258-5266 (Pubitemid 40471238)
60. Martinez Molina, D., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., and Nordlund, P. (2013) Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84-87
61. Plass, C., Pfister, S. M., Lindroth, A. M., Bogatyrova, O., Claus, R., and Lichter, P. (2013) Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat. Rev. Genet. 14, 765-780
62. Bjerke, L., Mackay, A., Nandhabalan, M., Burford, A., Jury, A., Popov, S., Bax, D. A., Carvalho, D., Taylor, K. R., Vinci, M., Bajrami, I., McGonnell, I. M., Lord, C. J., Reis, R. M., Hargrave, D., Ashworth, A., Workman, P., and Jones, C. (2013) Histone H3.3 mutations drive pediatric glioblastoma through up-regulation of MYCN. Cancer Discov. 3, 512-519
63. Hewings, D. S., Rooney, T. P., Jennings, L. E., Hay, D. A., Schofield, C. J., Brennan, P. E., Knapp, S., and Conway, S. J. (2012) Progress in the development and application of small molecule inhibitors of bromodomain-acetyl- lysine interactions. J. Med. Chem. 55, 9393-9413
64. Muller, S., Filippakopoulos, P., and Knapp, S. (2011) Bromodomains as therapeutic targets. Expert Rev. Mol. Med. 13, e29
65. Steiner, S., Magno, A., Huang, D., and Caflisch, A. (2013) Does bromodomain flexibility influence histone recognition? FEBS Lett. 587, 2158-2163
66. Sun, H., Liu, J., Zhang, J., Shen, W., Huang, H., Xu, C., Dai, H., Wu, J., and Shi, Y. (2007) Solution structure of BRD7 bromodomain and its interaction with acetylated peptides from histone H3 and H4. Biochem. Biophys. Res. Commun. 358, 435-441 (Pubitemid 46755725)
67. Prinjha, R. K., Witherington, J., and Lee, K. (2012) Place your BETs. The therapeutic potential of bromodomains. Trends Pharmacol. Sci. 33, 146-153